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Abstract
Background: Electroporation is a versatile method for in vitro or in vivo delivery of different
molecules into cells. However, no study so far has analysed the effects of electric pulses used in
electrochemotherapy (ECT pulses) or electric pulses used in electrogene therapy (EGT pulses) on
malignant cells. We studied the effect of ECT and EGT pulses on human malignant melanoma cells
in vitro in order to understand and predict the possible effect of electric pulses on gene expression
and their possible effect on cell behaviour.
Methods: We used microarrays with 2698 different oligonucleotides to obtain the expression
profile of genes involved in apoptosis and cancer development in a malignant melanoma cell line
(SK-MEL28) exposed to ECT pulses and EGT pulses.
Results: Cells exposed to ECT pulses showed a 68.8% average survival rate, while cells exposed
to EGT pulses showed a 31.4% average survival rate. Only seven common genes were found
differentially expressed in cells 16 h after exposure to ECT and EGT pulses. We found that ECT
and EGT pulses induce an HSP70 stress response mechanism, repress histone protein H4, a major
protein involved in chromatin assembly, and down-regulate components involved in protein
synthesis.
Conclusion: Our results show that electroporation does not significantly change the expression
profile of major tumour suppressor genes or oncogenes of the cell cycle. Moreover,
electroporation also does not changes the expression of genes involved in the stability of DNA,
supporting current evidence that electroporation is a safe method that does not promote
tumorigenesis. However, in spite of being considered an isothermal method, it does to some extent
induce stress, which resulted in the expression of the environmental stress response mechanism,
HSP70.
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Background
Electroporation, as a physical method for the delivery of
molecules into cells, was developed in 1982 [1]. However,
since then it has been developed not only for in vitro use
but also for in vivo use in a variety of applications [2]. Elec-
troporation is of interest as a gene delivery method
because, unlike transduction with viruses, it eliminates
the risks and limitations linked to the use of viruses. In
addition, in spite of extensive research, efficient and safe
chemical vectors have not yet been developed for in vivo
gene delivery [3]. Using appropriate electrical parameters,
destabilization of the membrane is reversible, ensuring a
high survival of permeabilized cells and the delivery of
non-permeant molecules inside the cell, bypassing the
normal internalisation route of these molecules [4].
The advantages of electroporation have recently been used
by different groups for a novel approach to introducing
chemotherapeutics in a variety of tumours, called electro-
chemotherapy [5-7]. Electrochemotherapy facilitates
chemotherapeutic drug delivery into cells by increasing
cell membrane permeability under specific electric pulses
[4]. It is an effective local treatment for patients with cuta-
neous and subcutaneous tumour nodules, on the basis of
the synergistic association of locally applied electric pulses
and low permeant chemotherapeutics such as bleomycin
and cisplatin. Moreover, several clinical trials with the
same chemotherapeutics showed a good response of
melanoma tumour nodules, as well as of other tumour
types [5,6,8-10].
As mentioned earlier, electrochemotherapy is not the only
application of electroporation. There are an increasing
number of applications in which electroporation might
be used. Electroporation is frequently used as a method of
in vitro transfection of genetic materials into prokaryotic
or eukaryotic cells. With the development of electric pulse
generators, the method has also been used in vivo for
naked DNA transfection in various rodent tissues, in order
to treat various diseases and for vaccination [11-13]. The
first clinical trial has also been reported for the treatment
of melanoma nodules in patients with plasmid DNA
encoding interleukin-12 [14].
The effect of electroporation on the level of cell genetic
response has only been studied in muscle cells [15,16].
However, the effect of ECT and EGT pulses on malignant
cells have not yet been analysed. In the present work,
therefore, we studied the effect of ECT and EGT pulses on
human malignant melanoma cells in vitro, in order to
understand and predict the possible effect of electric
pulses on gene expression and their possible effect on cell
behaviour.
Methods
Cell line
Human malignant melanoma cells SK-MEL28 (HBT-72;
American Type Culture Collection, USA) were grown as a
monolayer in minimum essential medium (MEM) with
Glutamax (Gibco, Paisley, UK), supplemented with 10%
fetal bovine serum (FBS; Gibco) and gentamicin (30 μg/
mL) (Gibco). Cells were routinely subcultured twice a
week and incubated in an atmosphere with 5% CO2 at
37°C.
Electroporation protocol
Confluent cell cultures were trypsinized, washed in MEM
with FBS for trypsin inactivation and once in electropora-
tion buffer (125 mM saccharose; 10 mM K2HPO4; 2.5 mM
KH2PO4; 2 mM MgCl2·6H2O) at 4°C. The final cell sus-
pension was prepared in electroporation buffer at 4°C, at
a concentration of 22 × 106 cells/mL. Aliquots of the final
cell suspension (3 × 106 cells) were placed between two
parallel electrodes with a 2 mm gap and subjected to eight
electric pulses for ECT pulses (electric field intensity 1300
V/cm, pulse duration 100 μs and frequency 1 Hz) or eight
electric pulses for EGT pulses (electric field intensity 600
V/cm, pulse duration 5 ms and frequency 1 Hz). Electric
pulses were generated by a GT-1 electroporator (Faculty of
Electrical Engineering, Ljubljana, Slovenia). One aliquot
of cell suspension was not subjected to any electric pulses
and served as the control treatment. After electroporation,
cells were incubated at room temperature for 5 minutes,
diluted in MEM with FBS and then plated in culture flasks
for 16 h for microarray assay.
Cell survival after electroporation
Clonogenic assay was used to determine cell survival after
electroporation. After exposure to ECT and EGT pulses,
SK-MEL28 were plated at a concentration of 500 cells/
dish. After 16 days, colonies were fixed, stained with crys-
tal violet and counted. The plating efficiency and the sur-
viving fraction were calculated. The experiments were
performed in triplicate and repeated three times.
RNA extraction
RNA from cells was isolated using TRI REAGENT™ (Sigma
Aldrich, St. Louis, USA) and the PureLink™ Micro-to-Midi
Total RNA Purification System (Invitrogen, Carlsbad,
USA), according to the manufacturer's instructions.
Briefly, 16 hours after electroporation, cells were
trypsinized, washed in MEM with FBS for trypsin inactiva-
tion and resuspended in PBS. After centrifugation at 1500
× g for 5 min, all excess liquid was removed and 1 mL of
TRI REAGENT™ was added to each sample. Samples were
mixed by hand for 15 s and allowed to stand for 2 – 15
min at room temperature. The resulting mixture was cen-BMC Cancer 2009, 9:299 http://www.biomedcentral.com/1471-2407/9/299
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trifuged at 12000 × g for 15 min at 4°C. The aqueous
phase was transferred to a fresh microcentrifuge tube and
an equal amount of 70% ethanol was added. Samples
were transferred to a PureLink™ Micro-to-Midi Total RNA
Purification System column (Invitrogen) and processed
according to the manufacturer's protocol. All samples
were washed from the column with 75 μl of RNAse free
water.
Analysis of RNA
The quality of RNA was checked on a Bioanalyzer 2100
(Agilent, Santa Clara, USA) using RNA 6000 Nano
Labchip (Agilent, Santa Clara, USA) and 6000 RNA ladder
as reference (Ambion, Austin, USA). The concentration
and quantity of RNA were determined with ND-1000
(Nanodrop, Wilmington, USA).
Preparation of aaRNA
Preparation of aaRNA was performed with an Amino Allyl
MessageAmp™ II aRNA Amplification Kit (Ambion)
according to the manufacturer's recommendations. For
each hybridization, we labelled 5 μg of non-exposed cells
(Cy3) and 5 μg of cells exposed to either ECT or EGT
pulses (Cy5) mRNA. After removing the excess dye, the
RNAs were dissolved in Nexterion Hybridization solution
(Schott Nexterion, Jena, Germany).
Microarrays
Microarrays were prepared with Human Apoptosis Subset
v2.0 and Human Cancer Subset v3.0 (Operon, Ebersberg,
Germany) 70 mer oligonucleotides and Nexterion 70 mer
Oligo Microarraying Kit (Schott Nexterion) slides. A sin-
gle array contained 2698 different genes, each gene being
replicated at least 4 times on each array. Oligonucleotides
were spotted using an MG1000 spotter (MicroGrid, Bos-
ton, USA), immobilised and stored according to the man-
ufacturer's instructions (Schott Nexterion). All
hybridisations were performed on HS400 in duplicate
(Tecan, Salzburg, Austria) according to the manufacturer's
instructions (Schott Nexterion). We used an LS200 scan-
ner (Tecan) at 6 μm resolution for scanning the microar-
rays.
Data analysis
We used Array-Pro Analyzer 4.5 (Media Cybernetics,
Bethesda, USA) for feature extraction after imaging of
microarrays. Acuity (Molecular devices, USA) was used for
the filtration of bad signals, LOWESS fit and microarray
data analysis. Features showing a signal intensity of more
than 65000 were flagged as bad. Features with a signal less
than 2 times the intensity of the background or coefficient
of variation (CV, ratio between standard deviation of the
background and the median feature intensity) greater
than 0.3 were considered not significantly expressed and
were filtered out. Log2 ratios were normalized using LOW-
ESS fit [17] and the median of four replicates was used to
calculate the average gene expression for a single sample.
We filtered out genes that were not expressed in all repli-
cate samples at least 1.5 times.
The Gene Ontology Tree Machine [18] program was used
for gene enrichment analysis. All other statistical analyses
were done using SPSS 16 (SPSS inc., Chicago, USA).
Results
Cell survival after electroporation
After electroporation of cells, cell viability was assessed by
clonogenic assay. Using this method, we determined a
68.8% average survival rate for cells exposed to ECT pulses
and a 31.4% average survival rate for cells exposed to EGT
pulses.
Microarrays
The difference in expression of genes involved in cancer
development was obtained by comparison of malignant
melanoma cells exposed to EGT or ECT pulses against the
Table 1: Genes differentially expressed in both ECT and EGT.
Name RefSeq Description Median
Log2 ratio
Down
RPL31 NM_000993 RIBOSOMAL PROTEIN L31 -1.42
CD28 NM_006139 T CELL SPECIFIC SURFACE GLYCOPROTEIN -0.78
H4FN NM_175054 HISTONE H4 -0.72
Up
NM_014486 NEURONAL THREAD PROTEIN 0.58
HSPA1B NM_005346 HEAT SHOCK 70 KDA PROTEIN 1 0.83
CDC25C NM_001790 M PHASE INDUCER PHOSPHATASE 3 0.70
CCNF NM_001761 G2/MITOTIC SPECIFIC CYCLIN F 0.79BMC Cancer 2009, 9:299 http://www.biomedcentral.com/1471-2407/9/299
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same untreated malignant melanoma cells. In our experi-
mental design, microarrays with 2698 different genes
were used as a dual colour system in which exposed and
non-exposed cells' mRNA were separately labelled, mixed
and hybridised together on each array. Only microarrays
expressing at least 50% of genes were used for further
analysis. All oligonucleotides on the same array were spot-
ted in quadruplicate and each microarray analysis was
performed in duplicate, thus obtaining eight measure-
ments of the same oligonucleotide. The acquired data
were analysed with Acuity 4.0 to select reliable signals.
Only genes, 1266 for ECT pulses and 1805 for EGT pulses,
present in both duplicated microarrays were considered
for further processing. We next checked the variability of
replicate measurements on Operon's microarray plat-
form. The average standard deviation of the Log2 ratio
(treated/untreated) of replicates exposed to ECT pulses
was 0.21, and 0.17 for replicates exposed to EGT pulses.
This gives a standard deviation of 1.16 fold and 1.12 fold
from the median value of replicates for ECT pulses and
EGT pulses, respectively. Out of 2698 different genes, 7
genes showed differential expression (Table 1), when the
groups of ECT and EGT pulses were combined. This repre-
sents roughly 0.26% of all genes present on a microarray.
However, looking at specifically different pulsation
parameters, ECT pulses yielded 34 differentially expressed
genes, which is roughly 1% of the interrogated genes,
whereas EGT pulses yielded 26 differentially expressed
genes, again accounting for roughly 1% of all interrogated
genes. When using a cut of value of 2.0, we found only 3
deregulated genes in the treatment with ECT pulses and
EGT pulses (Tables 2 and 3).
Table 2: Genes differentially expressed using ECT.
Name RefSeq Description Median
Log2 ratio
Down
RPL31 NM_000993 RIBOSOMAL PROTEIN L31 -1.52
RPS17 NM_001021 40S RIBOSOMAL PROTEIN S17 -1.09
TBCA NM_004607 TUBULIN SPECIFIC CHAPERONE A -1.08
PPIA NM_021130 PEPTIDYLPROLYL CISTRANS ISOMERASE A -0.97
S100B NM_006272 S100 PROTEIN, BETA CHAIN -0.94
NM_006471 MYOSIN REGULATORY LIGHT CHAIN 2 -0.93
RPA3 NM_002947 REPLICATION PROTEIN A 14 KDA SUBUNIT -0.89
NQO1 NM_000903 NAD(P)H DEHYDROGENASE [QUINONE] 1 -0.88
RPS6 NM_001010 40S RIBOSOMAL PROTEIN S6 -0.81
H4FN NM_175054 HISTONE H4 -0.80
EEF1A1 NM_001402 ELONGATION FACTOR 1 ALPHA 1 -0.77
ITGB4 NM_000213 INTEGRIN BETA4 PRECURSOR -0.76
CD28 NM_006139 T CELL SPECIFIC SURFACE GLYCOPROTEIN CD28 -0.75
H3F3A NM_002107 HISTONE H3.3 -0.74
CASP9 NM_001229 CASPASE 9 PRECURSOR -0.73
TNFRSF14 NM_003820 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 14 -0.65
CGB5 NM_033142 CHORIOGONADOTROPIN BETA CHAIN PRECURSOR -0.64
RPH3AL NM_006987 RABPHILIN 3 ALIKE -0.61
TFDP1 NM_007111 TRANSCRIPTION FACTOR DP-1 -0.60
CST3 NM_000099 CYSTATIN C PRECURSOR -0.59
Up
RB1 NM_000321 RETINOBLASTOMA 1 0.55
RIN2 NM_018993 RAS ASSOCIATION (RALGDS/AF6) DOMAIN CONTAINING PROTEIN 0.56
DNAJB1 NM_006145 DNAJ HOMOLOG SUBFAMILY B MEMBER 1 0.56
MATR3 NM_018834 MATRIN 3 0.57
HOXA4 NM_002141 HOMEOBOX PROTEIN HOXA4 0.65
RBBP4 NM_005610 CHROMATIN ASSEMBLY FACTOR 1 SUBUNIT C 0.70
CDC25C NM_001790 M PHASE INDUCER PHOSPHATASE 3 0.70
NM_014486 NEURONAL THREAD PROTEIN 0.73
GLIPR1 NM_006851 GLIOMA PATHOGENESIS RELATED PROTEIN 0.75
CRABP2 NM_001878 RETINOIC ACID BINDING PROTEIN II 0.77
RBL2 NM_005611 RETINOBLASTOMA LIKE PROTEIN 2 0.78
CCNF NM_001761 G2/MITOTIC SPECIFIC CYCLIN F 0.79
HSPA1B NM_005346 HEAT SHOCK 70 KDA PROTEIN 1 0.89
IL6 NM_000600 INTERLEUKIN 6 PRECURSOR (IL6) 0.98BMC Cancer 2009, 9:299 http://www.biomedcentral.com/1471-2407/9/299
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To find the possible biological processes involved in the
response to the electroporation procedure, we used the
Gene Ontology Tree Machine [18] program for gene
enrichment analysis. Our original dataset of genes was
compared against differentially expressed genes given in
Tables 2 and 3 to check whether there was any significant
gene enrichment in comparison to the original gene set.
Interestingly, we found significant enrichment of down-
regulated genes involved in biosynthesis, regulation of
viral genome replication and viral genome replication and
significant enrichment of deregulated genes involved in
cytokine production in melanoma cells exposed to ECT
pulses (Figure 1). Deregulated genes involved in cell divi-
sion, response to unfolded proteins and response to pro-
tein stimulus, were enriched in melanoma cells exposed
to EGT pulses (Figure 2).
In order to enable other users comprehensively to inter-
pret and evaluate our results, the original tables of com-
plete microarray results are available in the
supplementary data (see the GEO website at http://
www.ncbi.nlm.nih.gov/projects/geo Series entry:
GSE15420).
Discussion
In this study, we analysed the expression profile of malig-
nant melanoma cells for genes known to be involved in
the development of cancer. This was done in order to
assess whether electroporation could lead to an altered
expression profile of cells, possibly making them more
detrimental to patients. Our results show only minor dif-
ferences in the expression of genes involved in cancer
development. Overall, microarrays showed differential
expression of only 7 genes, when using a threshold value
of 1.5 fold and only 1 gene when using a threshold value
of 2.0 fold (Table 1). When calculating the standard devi-
ation of measurements across the microarray, we found it
to be very low (1.16 and 1.12 fold for ECT and EGT pulses
replicates) showing that the 1.5 fold threshold change is a
reasonable and reliable cut-off value. The results obtained
are also in agreement with studies performed so far
[15,16]. However, these studies used mouse muscle cells
Table 3: Genes differentially expressed using EGT.
Name RefSeq Description Median
Log2 ratio
Down
RET NM_020975 PROTOONCOGENE TYROSINEPROTEIN KINASE RECEPTOR -1.364
RPL31 NM_000993 RIBOSOMAL PROTEIN L31 -1.218
PC NM_022172 PYRUVATE CARBOXYLASE -1.009
NM_006590 SNRNP ASSEMBLY DEFECTIVE 1 HOMOLOG -0.931
IGFALS NM_004970 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN -0.895
CD28 NM_006139 T CELL SPECIFIC SURFACE GLYCOPROTEIN -0.845
CYP2A7 NM_000764 CYTOCHROME P450 2A7 -0.844
POLR2F NM_021974 DNA DIRECTED RNA POLYMERASE II -0.840
NM_007013 WW DOMAIN CONTAINING PROTEIN 1 -0.806
NM_004881 QUINONE OXIDOREDUCTASE HOMOLOG -0.795
TIMP2 NM_003255 METALLOPROTEINASE INHIBITOR 2 PRECURSOR -0.795
NM_005851 DOC1 RELATED PROTEIN (DOC1R) -0.753
H4FN NM_175054 HISTONE H4 -0.648
FGFR1 NM_023111 BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 PRECURSOR -0.599
LIG3 NM_013975 DNA LIGASE III -0.582
SKP2 NM_032637 S PHASE KINASE ASSOCIATED PROTEIN 2 -0.550
MUC4 NM_004532 MUCIN 4, ISOFORM D -0.549
PSMB7 NM_002799 PROTEASOME SUBUNIT BETA TYPE 7 PRECURSOR -0.544
PTPN21 NM_007039 PROTEIN TYROSINE PHOSPHATASE -0.539
SULT1C1 NM_001056 SULFOTRANSFERASE -0.520
HSPB2 NM_001541 HEATSHOCK PROTEIN, BETA2 -0.519
Up
NM_014486 NEURONAL THREAD PROTEIN 0.575
HSPA1B NM_005346 HEAT SHOCK 70 KDA PROTEIN 1 0.747
CDC25C NM_001790 MPHASE INDUCER PHOSPHATASE 3 0.759
TTYH1 NM_020659 TWEETY HOMOLOG 1 0.775
CCNF NM_001761 G2/MITOTICSPECIFIC CYCLIN F 0.777BMC Cancer 2009, 9:299 http://www.biomedcentral.com/1471-2407/9/299
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to account for any damage to tissue or difference in
expression profile made by electroporation for immuniza-
tion purposes. Hojman et al. observed only minor histo-
logical changes and no changes in muscle performance or
the gene expression profile of genes involved in cell death,
inflammation or muscle regeneration [15]. Similar results
were also obtained by Rubenstrunk et al. when they used
Stress/Toxicology Atlas cDNA expression arrays. The
group found only 2 genes out of 140 to be differentially
expressed and concluded that electroporation does not
induce expression of genes involved in stress and toxic
response [16]. Therefore, despite the fact that only single
cell line was used in our study, it is reasonable to expect
that other cell lines would behave in similar way.
Interestingly, one of the seven differentially expressed
genes is the stress response gene HSPA1B. HSPA1B is a
member of the HSPA family of HSP70 proteins and is the
strongest stress inducible member of the HSPA family
[19]. It has been proposed that HSPA1B is a part of the
molecular chaperon network that protects the proteome
against environmental stress [20]. This shows that cells
exposed to either of the electroporation protocols are
exposed to the stress arising to some extent from a protein
denaturation, and therefore over-express HSP70. This
observation is also supported by the overexpression of
DNAJB1 in cells treated with ECT pulses. DNAJB1, con-
taining a conserved sequence motif (HPD) in the J
domain is known to be critical for the acceleration of the
ATPase activity of HSP70 [19].
Another interesting observation was downregulation of
the histone protein H4 in both treatment protocols and a
significant enrichment of downregulated genes involved
in protein synthesis. Both results indicate a stall in DNA
assembly to chromosomes and biosynthesis of proteins,
which could arise from stress.
Conclusion
Overall, our results clearly show that electroporation does
not significantly changes the expression profile of major
tumour suppressor genes or oncogenes of the cell cycle.
Electroporation also does not change the expression of
genes involved in the stability of DNA, therefore support-
ing the notion that electroporation is a safe method that
does not promote tumorigenesis. However, in the present
Gene enrichment analysis for cell line exposed to ECT pulses Figure 1
Gene enrichment analysis for cell line exposed to ECT pulses. Expected – number of genes expected to be differen-
tially expressed. Observed – number of genes differentially expressed. In red are GO biological functions significantly enriched 
in the cell line exposed to ECT pulses.BMC Cancer 2009, 9:299 http://www.biomedcentral.com/1471-2407/9/299
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study, we showed that to some extent electroporation
induces HSP70, resulting in the activation of the environ-
mental stress response mechanism.
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